Olanzapine (Zyprexa Relprevv) vs Ziprasidone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Olanzapine (Zyprexa Relprevv)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00088478 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial of 402 patients. All three tested doses of the long-acting olanzapine injection produced a significantly greater reduction in psychiatric symptom severity (PANSS) than placebo.
Reported efficacy
Demonstrate superiority of IM olanzapine depot 300 mg/2 weeks, 405 mg/4 weeks, and 210 mg/2 weeks dosages compared with placebo in the treatment of patients with schizophrenia: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each). (met)
Result source: NCT00088478
Ziprasidone
Marketed by Viatris and partners
NCT00159770 · Phase 3 · completed
This 12-week, open-label, multicentre trial randomized 293 patients with chronic schizophrenia to ziprasidone (n=147) or to a comparator group of olanzapine, risperidone or quetiapine chosen by the investigator (n=146). The primary endpoint was total PANSS score, tested for non-inferiority with a margin of 7 points to the disadvantage of ziprasidone. Ziprasidone was non-inferior to the comparator group on total PANSS and on all subscores (P<0.0001), so the primary endpoint was met. The figures come from the peer-reviewed paper (Lublin et al., World J Biol Psychiatry 2009), whose abstract does not give a confidence interval.
Next expected readout: February 2027 · NCT03781115 (registry estimate)
Reported efficacy
Number of Events Recorded Based on Ziprasidone Side Effects Checklist During Randomized Trial (From Baseline up to Week 8); Change From Baseline in Simpson Angus Scale for Extrapyramidal Symptoms (SAS) (Baseline, Week 2, Week 4, Week 6, Week 8); Change From Baseline in the Barnes Akathisia Scale (BAS) (Baseline, Week 2, Week 4, Week 6, Week 8); Number of Participants With High and Low Levels in Serum Prolactin Concentration (Baseline, Week 8); Vital Signs: Systolic and Diastolic Blood Pressure Levels (Baseline, Week 1, Week 2, Week 4, Week 6, Week 8); Electrocardiogram (EKG): Number of Participants With an Increase From Baseline to Corrected QT (QTc) Interval >/= 500 Milliseconds (Msec) (6 hours after dosing of Weeks 1, 2 and 8); Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline, Week 2, Week 4, Week 6, Week 8); Percentage of Participants With Response (Baseline, Week 2, Week 4, Week 6, Week 8); Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score (Baseline, Week 2, Week 4, Week 6, Week 8); Number of Treatment-emergent Adverse Events During Randomized Trial (From Baseline up to Week 8): Change from baseline in PANSS total score at Week 8, high-dose ziprasidone (320 mg/day) vs standard dose (160 mg/day plus placebo capsules): -8.62 vs -5.48, mixed-model difference -1.37 (95% CI -7.20 to 4.45), p=0.642. No registered primary favoured the high dose; the Simpson-Angus extrapyramidal score was worse on the high dose at Week 2 (difference 1.02, 95% CI 0.08 to 1.95, p=0.033). (missed)
Result source: NCT00403546
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Olanzapine (Zyprexa Relprevv) | Ziprasidone |
|---|---|---|
| PANSS total, change | —Not posted · NCT00088491 | —Not posted · NCT00159770 |
| CGI-S, change | -0.4 vs -0.3vs Oral OlanzapineNCT00320489 | -1.2 vs -1.2vs HaloperidolNCT00723606 |
| PANSS response | —Not posted · NCT00088491 | —Not posted · NCT00159770 |
| PSP, change | —Not posted · NCT00088491 | —Not posted · NCT00159770 |
| Relapse (% of patients) | 20.1% vs 18.5%vs Oral OlanzapineNCT00320489 | —Not posted · NCT00159770 |
PANSS total, change
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Ziprasidone
- —Not posted · NCT00159770
CGI-S, change
- Olanzapine (Zyprexa Relprevv)
- -0.4 vs -0.3vs Oral OlanzapineNCT00320489
- Ziprasidone
- -1.2 vs -1.2vs HaloperidolNCT00723606
PANSS response
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Ziprasidone
- —Not posted · NCT00159770
PSP, change
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Ziprasidone
- —Not posted · NCT00159770
Relapse (% of patients)
- Olanzapine (Zyprexa Relprevv)
- 20.1% vs 18.5%vs Oral OlanzapineNCT00320489
- Ziprasidone
- —Not posted · NCT00159770
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. Olanzapine (Zyprexa Relprevv): 7 of 7 rows · Ziprasidone: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Olanzapine (Zyprexa Relprevv) Rows use multiple source trials | Ziprasidone Rows use multiple source trials |
|---|---|---|
| BPRS Total absolute change · score | -0.96 vs -0.91 Oral Olanzapine score @ 104wka,b,c NCT00320489 · Phase 3 · monotherapy | -17.32 vs -18.44 Haloperidol score @ 0.43wka,b,c NCT00723606 · Phase 3 · registry result, not featured evidence |
| CGI-S absolute change · score No placebo or comparator arm | -0.17 score @ 313wkd,a,b,e NCT00088465 · Phase 3 · registry result, not featured evidence | -0.76 score @ 16wkd,a,b,e NCT00406315 · Phase 4 · registry result, not featured evidence |
| PANSS Total absolute change · score No placebo or comparator arm | 0.3 score @ 330wka,b,f NCT00088465 · Phase 3 · registry result, not featured evidence | -8.62 score @ 8wkHigh dosea,b,f NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 |
| Dropout rate | 54.9%g NCT00320489 · Phase 3 · monotherapy show 1 more result60.3% NCT00088465 · Phase 3 · registry result, not featured evidence | —High doseh NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 show 9 more results—High dose NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 26.8% NCT00338949 · Phase 4 · registry result, not featured evidence 58.5% NCT00406315 · Phase 4 · registry result, not featured evidence 12.5% NCT00351000 · Phase 4 · registry result, not featured evidence 2.1% NCT00723606 · Phase 3 · registry result, not featured evidence 99.1% NCT00139737 · Phase 3 · registry result, not featured evidence 88.4% NCT00174447 · Phase 3 · registry result, not featured evidence 35.7% NCT00538642 · Phase na · registry result, not featured evidence 0% NCT00225498 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 9.8%g NCT00320489 · Phase 3 · monotherapy show 1 more result8.3% NCT00088465 · Phase 3 · registry result, not featured evidence | —High doseh NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 show 9 more results—High dose NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 — NCT00338949 · Phase 4 · registry result, not featured evidence 16.2% NCT00406315 · Phase 4 · registry result, not featured evidence — NCT00351000 · Phase 4 · registry result, not featured evidence 1.1% NCT00723606 · Phase 3 · registry result, not featured evidence 16.9% NCT00139737 · Phase 3 · registry result, not featured evidence 44.2% NCT00174447 · Phase 3 · registry result, not featured evidence — NCT00538642 · Phase na · registry result, not featured evidence — NCT00225498 · Phase na · registry result, not featured evidence |
| Serious AEs | 9.5%g NCT00320489 · Phase 3 · monotherapy show 1 more result18.3% NCT00088465 · Phase 3 · registry result, not featured evidence | —High doseh NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 show 9 more results10.5%High dose NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 6.7% NCT00338949 · Phase 4 · registry result, not featured evidence 9.1% NCT00406315 · Phase 4 · registry result, not featured evidence 0% NCT00351000 · Phase 4 · registry result, not featured evidence 0% NCT00723606 · Phase 3 · registry result, not featured evidence 9.7% NCT00139737 · Phase 3 · registry result, not featured evidence 30.2% NCT00174447 · Phase 3 · registry result, not featured evidence 0% NCT00538642 · Phase na · registry result, not featured evidence 0% NCT00225498 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | show 1 more resultweight increased 14.4% anxiety 9.7% insomnia 9.7% NCT00088465 · Phase 3 · registry result, not featured evidence | High doseh hypertension 18.4% somnolence 15.8% headache 10.5% NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 show 6 more resultsinsomnia 19.1% somnolence 14.5% nausea 11.6% NCT00406315 · Phase 4 · registry result, not featured evidence difficulty breathing 4.2% dizziness 4.2% NCT00351000 · Phase 4 · registry result, not featured evidence dizziness 3.7% somnolence 3.7% akathisia 3.2% NCT00723606 · Phase 3 · registry result, not featured evidence electrocardiogram qt prolonged 13.9% insomnia 6.3% anxiety 4.5% NCT00139737 · Phase 3 · registry result, not featured evidence anxiety 23.3% insomnia 16.3% schizophrenia 14% NCT00174447 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 0.43 weeks versus 104 weeks.
- dTrial phases differ: Phase 4 versus Phase 3.
- eAssessment timepoints differ: 16 weeks versus 313 weeks.
- fAssessment timepoints differ: 8 weeks versus 330 weeks.
- gPopulation comparability has not been reviewed for these studies.
- hPopulation comparability has not been reviewed for 8 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olanzapine (Zyprexa Relprevv)
+ 11 further endpoints in the CSV export.
Ziprasidone
show 3 more results
show 1 more result
show 2 more results
+ 17 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (Zyprexa Relprevv)'s landscape · Ziprasidone's landscape